Oncology startup to double size with $152M
With a freshly inked deal with Pfizer and an additional $152 million in its pocket, Cambridge, Massachusetts startup Pyxis Oncology is prepared to get its drugs into the clinic.
Founded in 2019 by life sciences venture capital firm the Longwood Fund, Pyxis has three drug candidates in the works, all of which are antibody-drug compounds designed to target various forms of cancer. Two of the candidates, PYX-201 and PYX-203, were in-licensed from Pfizer, and a third, PYX-202 , was in-licensed from South…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news
More News: Cancer | Cancer & Oncology | Health Management | Pfizer | Pharmaceuticals | Venture Capital